We are live on
!
Find out more
Two Sigma Investments Portfolio holdings
AUM
$124B
1-Year Est. Return
33.93%
This Fund
S&P 500
This Quarter
Est. Return
+9.67%
1 Year Est. Return
+33.93%
3 Year Est. Return
+96.56%
5 Year Est. Return
+105.93%
10 Year Est. Return
+538.88%
AUM
$42.6B
AUM Growth
-$927M
(-2.1%)
Cap. Flow
-$4.42B
Cap. Flow
% of AUM
-10.38%
Top 10 Holdings %
Top 10 Hldgs %
9.02%
Holding
3,518
New
408
Increased
1,022
Reduced
1,392
Closed
532
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$244M |
| 2 |
Pfizer
PFE
|
+$234M |
| 3 |
Nike
NKE
|
+$201M |
| 4 |
Tesla
TSLA
|
+$200M |
| 5 |
S&P Global
SPGI
|
+$196M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$305M |
| 2 |
Advanced Micro Devices
AMD
|
+$241M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$231M |
| 4 |
Merck
MRK
|
+$199M |
| 5 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$190M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.1% |
| 2 | Healthcare | 11.63% |
| 3 | Consumer Discretionary | 11.09% |
| 4 | Financials | 10.76% |
| 5 | Industrials | 9.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2101
ALX Oncology
ALXO
$290M
| $730K | ﹤0.01% |
65,455
-466
| -0.7% | -$6.54K |
|
2102
PUT
Arbor Realty Trust
ABR
$998M
| $729K | ﹤0.01% |
55,000
-315,300
| -85% | -$4.23M |
|
|
ME
2103
DELISTED
23andMe Holding Co
ME
| $726K | ﹤0.01% |
68,279
+24,689
| +57% | +$318K |
|
2104
PUT
Bread Financial
BFH
$4.38B
| $726K | ﹤0.01% |
19,500
-500
| -3% | -$17.7K |
|
2105
Viemed Healthcare
VMD
$371M
| $725K | ﹤0.01% |
76,850
+9,145
| +14% | +$78.4K |
|
2106
Henry Schein
HSIC
$9.82B
| $724K | ﹤0.01% |
+9,588
| New | +$719K |
|
2107
Braskem
BAK
$913M
| $724K | ﹤0.01% |
68,729
-61,815
| -47% | -$504K |
|
2108
Deluxe
DLX
$1.15B
| $722K | ﹤0.01% |
35,063
+3,780
| +12% | +$75.1K |
|
2109
iHeartMedia
IHRT
$583M
| $721K | ﹤0.01% |
345,136
-570,437
| -62% | -$1.34M |
|
2110
Acumen Pharmaceuticals
ABOS
$176M
| $720K | ﹤0.01% |
177,901
-66,515
| -27% | -$251K |
|
2111
Tetra Tech
TTEK
$9.07B
| $720K | ﹤0.01% |
19,500
-80,000
| -80% | -$2.77M |
|
|
FITB
2112
Fifth Third Bancorp
FITB
$51.8B
| $718K | ﹤0.01% |
19,300
| – | – |
|
2113
Tecnoglass Holdings Inc.
TGLS
$1.96B
| $718K | ﹤0.01% |
13,800
-53,751
| -80% | -$2.47M |
|
2114
Fossil Group
FOSL
$318M
| $717K | ﹤0.01% |
703,046
-44,796
| -6% | -$50K |
|
2115
First Financial Bancorp
FFBC
$3.53B
| $716K | ﹤0.01% |
+31,929
| New | +$711K |
|
2116
Zeta Global
ZETA
$6.69B
| $715K | ﹤0.01% |
65,414
-159,948
| -71% | -$1.6M |
|
2117
Amneal Pharmaceuticals
AMRX
$5.79B
| $713K | ﹤0.01% |
117,666
-93,503
| -44% | -$527K |
|
|
BCYC
2118
Bicycle Therapeutics
BCYC
$292M
| $712K | ﹤0.01% |
28,585
-75,043
| -72% | -$1.59M |
|
|
DSKE
2119
DELISTED
Daseke, Inc. Common Stock
DSKE
| $712K | ﹤0.01% |
85,732
-49,900
| -37% | -$409K |
|
2120
Accuray
ARAY
$34M
| $711K | ﹤0.01% |
287,992
-4,981
| -2% | -$13.3K |
|
2121
Motley Fool 100 Index ETF
TMFC
$2.12B
| $709K | ﹤0.01% |
14,300
+100
| +0.7% | +$4.74K |
|
2122
Dr. Reddy's Laboratories
RDY
$10.2B
| $708K | ﹤0.01% |
48,255
-205,555
| -81% | -$3M |
|
2123
XPO
XPO
$23.7B
| $708K | ﹤0.01% |
5,800
-42,800
| -88% | -$4.58M |
|
2124
Pacific Biosciences
PACB
$370M
| $708K | ﹤0.01% |
188,692
+115,119
| +156% | +$674K |
|
2125
Bank of N.T. Butterfield & Son
NTB
$2.45B
| $707K | ﹤0.01% |
22,116
+2,740
| +14% | +$83.3K |
|
Similar funds
VAM
Two Sigma Investments's Q1 2024 Portfolio in Review
As of Q1 2024, Two Sigma Investments held 3,518 positions worth $42.6B, down 2.1% from $43.5B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Two Sigma Investments withdrew a net $4.42B in Q1 2024, closing 532 positions and reducing 1,392 holdings. Its most notable exit was Rivian, an estimated $158M position sold in full.
By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 18% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Two Sigma Investments opened a new position in Pfizer worth $234M.
- Two Sigma Investments's largest Q1 2024 buy was Pfizer: 8,419,014 shares worth $234M.
- Two Sigma Investments added most to Gilead Sciences in Q1 2024, an estimated $244M increase.
- Two Sigma Investments's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $305M.
- Two Sigma Investments fully exited Rivian in Q1 2024, selling an estimated $158M.
- Two Sigma Investments's ten largest holdings make up 9% of its $42.6B portfolio in Q1 2024.
- Two Sigma Investments opened 408 new positions and closed 532 in Q1 2024.
- Two Sigma Investments's portfolio value fell 2.1% quarter-over-quarter to $42.6B.
Based on Two Sigma Investments's 13F filing for Q1 2024, filed 15 May 2024.